Personalized Cancer Care. Realized.
Forging a Clearer Path to Cancer Treatments
Allarity Therapeutics CEO Letter to Shareholders: Read the letter from CEO James G. Cullem to Allarity’s shareholders and other stakeholders, published on August 11, 2023
Allarity Therapeutics is a clinical-stage precision medicine company actively advancing a pipeline of in-licensed oncology therapeutics for patients with difficult-to-treat cancers. The company is leveraging its proprietary, highly accurate Drug Response Predictor (DRP®) technology to refine patient selection and improve clinical outcomes. Publicly traded on NASDAQ, Allarity (ALLR) is headquartered in Boston, MA, while maintaining an R&D facility in Hoersholm, Denmark. Allarity is committed to enhancing patient outcomes through improved decision-making and personalized cancer care.